Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue TEL AVIV, Israel — Chemomab Therapeutics Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...
Latest News
TEL AVIV, Israel — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis (PSC) were published in the current...
TEL AVIV, Israel — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease...
TEL AVIV, Israel — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced the publication of a new study that further confirms the key role of its novel soluble protein target CCL24 in systemic sclerosis...
According to the results of a phase 3 study published in Blood Advances, the antisense oligonucleotide (ASO) oblimersen can be added safely to conventional chemotherapy for older patients with acute myeloid leukemia (AML), and although adding the ASO did not improve complete remission (CR) rates, it appeared to improve disease-free survival...
A Chennai hospital has done for six-month-old Tanisha, born with an “ineffective and underdeveloped” right lung and a “very large vessel” supplying blood to it, what hospitals in her hometown Calcutta could not — give her a new lease of life. One in a lakh babies suffers from the defect,...
Chiba, Japan – Metastatic melanoma, also known as stage IV melanoma, is a type of skin cancer that spreads to other parts of the body. It is one of the most aggressive forms of skin cancer, with current therapies—including immunotherapy and targeted drugs—showing limited effectiveness. Radiotherapy is an emerging treatment...
BOSTON — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced a collaboration with the National Alliance on Mental Illness (NAMI), the nation’s largest grassroots mental health organization, to offer new mental health...
BOSTON, Mass. — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, is pleased to announce the Health Canada approval of MYALEPTA™ (metreleptin for injection). As an adjunct to diet, MYALEPTA is indicated as a...
BOSTON, Mass. — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases. “There continues to...